VTGN - VistaGen slips as mid-stage plans for anxiety therapy remains on hold
- Shares of clinical-stage biotech VistaGen Therapeutics ( NASDAQ: VTGN ) lost ~20% Wednesday after the company said that it has yet to decide on resuming a Phase 2 trial for its anxiety disorder candidate PH94B.
- Recently, the company has proposed adjustments to the Phase 2 trial PALISADE-2 after learning in July that its Phase 3 clinical trial for PH94B PALISADE-1 did not meet the primary endpoint in adults with social anxiety disorder (SAD).
- Before receiving regulatory feedback and evaluating the impact of proposed adjustments, the company “believes it is not yet advisable to make a decision about resuming PALISADE-2,” VistaGen ( VTGN ) said.
- The company also attributed its decision to two failed public speaking challenge SAD studies conducted by rivals.
- The disclosure came alongside VistaGen’s ( VTGN ) Q4 2022 results which met the consensus for earnings but fell short of revenue forecasts on Tuesday.
- In December, Vanda Pharmaceuticals ( VNDA ) announced Phase 2 results for its performance anxiety candidate QW-765.
For further details see:
VistaGen slips as mid-stage plans for anxiety therapy remains on hold